Bio-Path Holdings (NASDAQ: BPTH) Stock Skyrockets After Receiving Patent For Prexigebersen
Hasnain R
October 22, 2020
Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced today that its lead product candidate, prexigebersen, in combination with front line cytidine analogues or Bcr-Abl tyrosine kinase inhibitors,